Hereditary C1 inhibitor deficiency presenting in patients who are pregnant or breastfeeding (lactating). The choice of therapy in this setting is guided by the specific safety considerations that apply to both mother and infant.
Patients with hereditary C1 inhibitor deficiency during pregnancy or lactation. Preferred therapies for these groups are specifically identified in the evidence-based guidance — not all treatment options used outside of pregnancy are appropriate in this context.
When certain preferred agents are not available, a plasma-based therapeutic option may be used. The full protocol specifies preferred therapies, the conditions under which alternatives apply, and the complete clinical decision pathway.
Full regimen, sequencing, and clinical criteria available in the complete protocol below.
DOI: 10.1111/all.15214
View source ↗